



PRESS RELEASE

Samumed Announces Multiple Presentations at the European League Against Rheumatism (EULAR) 2018 Annual Congress

SAN DIEGO – June 08, 2018 - Samumed, LLC, announced today that it will present clinical and preclinical data on two of the company’s investigational drugs, SM04690, for the treatment of osteoarthritis (OA), and SM04755, for the treatments of psoriasis and tendinopathy, at the European League Against Rheumatism (EULAR) 2018 Annual European Congress of Rheumatology to be held in Amsterdam from June 13-16, 2018.

In addition to data on its investigational candidates, Samumed will also be presenting data contributing to the knowledge base on the design of knee osteoarthritis clinical trials relevant to the development of new therapies.

“We are pleased to have the opportunity to present clinical and preclinical data at EULAR from a wide spectrum of our programs including OA, psoriasis, and tendinopathy,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. “We look forward to presenting Phase 2 clinical data on SM04690, our small molecule candidate for knee OA with disease modifying potential.”

Oral presentation details:

Abstract Title	Date/Time	Session Title
Treatment of knee osteoarthritis with SM04690 improved WOMAC A1 “pain on walking” – results from a 52 week, randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, Wnt pathway inhibitor Presentation #OP0061	Wednesday, June 13 5:30 p.m. CET	Abstract Session: Envisioning new horizons for people with osteoarthritis

Poster presentation details:

Abstract Title	Date/Time	Session Title
Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasis Presentation #THU0046	Thursday, June 14 11:45 a.m. CET	Poster Session I
Experimental tendinopathy treatment with SM04755, a topical small molecule inhibitor of the Wnt pathway Presentation #THU0522	Thursday, June 14 12:50 p.m. CET	Poster Tour: Pain in the joint; managing a widespread problem

Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a Wnt pathway inhibitor, SM04690, for knee osteoarthritis treatment Presentation #FRI0534	Friday, June 15 11:45 a.m. CET	Poster Session II
Potential nociceptive pain relief of intra-articular saline control in clinical trials of knee osteoarthritis: a systematic review and meta-analysis of randomized trials Presentation #FRI0542	Friday, June 15 11:45 a.m. CET	Poster Session II
SM04690, a Wnt pathway inhibitor: anti-inflammatory and cartilage protective effects in preclinical OA models Presentation #FRI0552	Friday, June 15 11:45 a.m. CET	Poster Session II
Adjusting for the intra-articular placebo effect in knee osteoarthritis therapies Presentation #SAT0565	Saturday, June 16 10:30 a.m. CET	Poster Session III
Results from a 52 week randomized, double-blind, placebo-controlled, phase 2 study of a novel, Wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment Presentation #SAT0586	Saturday, June 16 10:30 a.m. CET	Poster Session III

Further details can be found on the EULAR website at <https://www.congress.eular.org/index.cfm>. A copy of the presentation materials can be accessed by visiting the [Publications](#) section of the Samumed website after the presentations conclude.

About the European League Against Rheumatism (EULAR)

The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.

About SM04690

SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection, and is being developed as a potential disease-modifying drug for osteoarthritis (DMOAD). Preclinical data suggested SM04690 has a dual mechanism of action with three specific effects on joint health – generation of articular cartilage, slowing down cartilage degradation, and reducing inflammation in the joint. Additional information on Samumed’s SM04690 osteoarthritis program can be found here: <https://www.samumed.com/pipeline/detail.aspx?id=20>

samumed

About SM04755

SM04755 is a small-molecule Wnt pathway inhibitor and is being developed as a potential topical therapeutic for tendinopathy. Preclinical data suggested that SM04755 may inhibit inflammation, reduce fibrosis, and increase tenocyte differentiation (tendon repair). Additional information on Samumed's SM04755 tendinopathy program can be found here:

<https://www.samumed.com/pipeline/detail.aspx?id=13>

SM04755 is also being developed as a topical treatment for psoriasis. Preclinical data suggested SM04755 has the potential to attenuate inflammation, epidermal thickening, and fibrosis. Additional information on Samumed's SM04755 psoriasis program can be found here:

<https://www.samumed.com/pipeline/detail.aspx?id=11>

About Samumed

Samumed's small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed's potential regenerative therapeutics and broad clinical pipeline at

<https://www.samumed.com/pipeline/default.aspx>

Corporate Contact:

Erich Horsley

Samumed, LLC

erich@samumed.com

858-365-0200

Investor Contact:

Ashley Robinson

LifeSci Advisors

arr@lifesciadvisors.com

617-535-7742

Media Contact:

Matt Middleman, M.D.

LifeSci Public Relations

matt@lifescipublicrelations.com

646-627-8384